An interventional study of Care Buddy in Dementia, sponsored by Duke-NUS Graduate Medical School. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Duke-NUS Graduate Medical School · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Dementia with a site in Singapore — 7 open to participants now, 9 under way, none of them phase 3. Dementia · Singapore.
Among the 25 studies in Dementia with a site in Singapore, this one is the 12th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2025, is one of 14 with no phase, and was the 19th registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →7 of the 25 studies in Dementia with a site in Singapore are open now. Recruiting first, the newest first:
National University of Singapore · Sites in Singapore
Ages 45–80 · Healthy volunteers
National Cancer Centre, Singapore · Sites in Singapore
Ages 50–99
Eli Lilly and Company · Sites in Singapore, United States, Australia and 1 more country
Ages 50–85
Vincent Tay Khwee Soon · Sites in Singapore
Ages 50–80
Changi General Hospital · Sites in Singapore
Ages 21–100
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 21 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 3
First in 2003; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 210 is above the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 225 across the 22 interventional studies, 400 across the 3 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 25 have an industry lead sponsor. The 10 most frequent:
Duke-NUS Graduate Medical School is the lead sponsor of 63 studies on the registry; 6 are open to participants now.
Duke-NUS Graduate Medical School has 5 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
3 of the studies in Dementia with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06268886Bristol-Myers SquibbStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | 2026-12-17 |
| NCT07598370Eli Lilly and CompanyA Study of LY3439539 in Participants With Alzheimer's Disease | 2027-08 |
| NCT07234357National Cancer Centre, SingaporeSensory Enrichment Using Aromatherapy for Neurobehavioral and Psychological Symptoms in Early Dementia | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies in Dementia with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to develop a mobile-app (Care Buddy) which will be a one-stop integrated source of information and technology-based solutions for caregivers of people with dementia (PWDs). Study aims to bring caregivers into closer partnerships with the wider ecosystem (e.g., healthcare practitioners, community services, peer support, and care service providers) which will ultimately improve outcomes for both PWDs and their caregivers.
This is a 5-year study with various stages: 1) proof-of-concept stage to design and develop the Care buddy intervention, 2) proof-of-value stage to assess the feasibility, acceptability and satisfaction with the Care buddy intervention among informal caregivers of PWDs, 3) test-bedding stage to assess the efficacy and cost-effectiveness of the Care buddy intervention versus usual care among informal caregivers of PWDs with help of a multi-centre 2-arm RCT and 4) deployment stage to scale up the intervention at multiple centres across Singapore, monitor its adoption and outcomes and assess any organizational and individual barriers to adoption.
By the end of the proposed five-year project, investigators aim to develop and evaluate the technology as well as achieve widespread adoption among caregivers of PWDs. Investigators want to enable easy access to information, provide decisional and social support, improve the reach and uptake of existing community service providers, and assist with coordination among multiple informal and professional caregivers through the journey of dementia caregiving and into the bereavement phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The inclusion criteria for patients are
Exclusion Criteria:
Caregivers of person with dementia who will be randomized in this arm will have access to the CareBuddy mobile app on their phone. They will be using this app for 1 year and will be followed up every 2 months.
Device: Care Buddy
Caregivers of person with dementia who will be randomized in this arm will continue usual care for their loved one. They will be enrolled for 1 year and will be followed up every 2 months.
Care Buddy mobile intervention will be a one-stop solution for caregivers of dementia patients and help them in their care-giving journey by providing them solutions to manage behavioural problems, physical conditions of their loved one. The app will be multi-component and will provide tools for the caregiver to manage their stress and burden. It will provide information on dementia, list of service providers, information on grief, financial support. This app will provide a platform for all enrolled caregivers to chat with each other and provide social support.
Caregiver Psychological well-being
Flourish - range - 8 - 56, high score represents a person with many psychological resources and strengths
Time frame: 1 year from data collection
Caregiver social scale
Friendship scale - The score range is 0-24. A high score represents social connectedness and a score of "0" complete social isolation
Time frame: 1 year from data collection
Caregiver Dementia Knowledge
The Dementia Knowledge Assessment Tool - range - 0-21. High score equals to higher knowledge of dementia.
Time frame: 1 year from data collection
Caregiver Impact
Revised Memory \& Behavior Problem checklist - range - 0-96 Higher score indicates increased impact.
Time frame: 1 year from data collection
Caregiver Burden
Zarit Burden scale - range 0-88. 0 - 21 little or no burden, 21 - 40 mild to moderate burden, 41 - 60 moderate to severe burden, 61 - 88 severe burden \>34 - clinically significant burden.
Time frame: 1 year from data collection
Caregiver Stress
Perceived Stress Scale: Scoring: PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 \& 4 = 0) to the four positively stated items (items 4, 5, 7, \& 8) and then summing across all scale items.
Time frame: 1 year from data collection
Health care costs
Health care costs, hospitalizations and emergency room visits for caregivers and PWDs will be obtained from patient billing data.
Time frame: 1 year from data collection
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for May 2026, 13 months after the start.
Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 13 months is below that.
Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Duke-NUS Graduate Medical School